These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 31566020)

  • 1. Treatment of pemphigus vulgaris: part 1 - current therapies.
    Yanovsky RL; McLeod M; Ahmed AR
    Expert Rev Clin Immunol; 2019 Oct; 15(10):1047-1060. PubMed ID: 31566020
    [No Abstract]   [Full Text] [Related]  

  • 2. Pemphigus vulgaris: approach to treatment.
    Sinha AA; Hoffman MB; Janicke EC
    Eur J Dermatol; 2015 Apr; 25(2):103-13. PubMed ID: 25547117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of pemphigus vulgaris: part 2 - emerging therapies.
    Yanovsky RL; McLeod M; Ahmed AR
    Expert Rev Clin Immunol; 2019 Oct; 15(10):1061-1071. PubMed ID: 31575295
    [No Abstract]   [Full Text] [Related]  

  • 4. Successful treatment with mycophenolate mofetil of four Japanese patients with pemphigus vulgaris.
    Koga H; Ishii N; Hamada T; Karashima T; Nakama T; Yasumoto S; Hashimoto T
    Eur J Dermatol; 2010; 20(4):472-5. PubMed ID: 20406724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First line treatment of pemphigus vulgaris with a novel protocol in patients with contraindications to systemic corticosteroids and immunosuppressive agents: Preliminary retrospective study with a seven year follow-up.
    Ahmed AR; Nguyen T; Kaveri S; Spigelman ZS
    Int Immunopharmacol; 2016 May; 34():25-31. PubMed ID: 26919279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of current therapy and clinical outcome in childhood pemphigus vulgaris.
    Mabrouk D; Ahmed AR
    Pediatr Dermatol; 2011; 28(5):485-93. PubMed ID: 21883426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Consensus on the treatment of autoimmune bullous dermatoses: pemphigus vulgaris and pemphigus foliaceus - Brazilian Society of Dermatology.
    Porro AM; Hans Filho G; Santi CG
    An Bras Dermatol; 2019 Apr; 94(2 Suppl 1):20-32. PubMed ID: 31166407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current and future treatment options for pemphigus: Is it time to move towards more effective treatments?
    Tavakolpour S
    Int Immunopharmacol; 2017 Dec; 53():133-142. PubMed ID: 29107213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Prolonged complete clinical remission in patients with severe pemphigus vulgaris after cycles of intravenous cyclophosphamide].
    España Alonso A; Panizo C; Fernández S; Marquina M; Pretel M; Aguado L; Sánchez-Ibarrola A
    Actas Dermosifiliogr; 2009 Mar; 100(2):113-20. PubMed ID: 19445875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic evaluation of mycophenolate mofetil for pemphigus.
    Doukaki S; Pistone G; Aricò M; Bongiorno MR
    Expert Opin Drug Metab Toxicol; 2011 Feb; 7(2):237-44. PubMed ID: 21192770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of cyclophosphamide, azathioprine, and cyclosporine (ciclosporin) as adjuvant drugs in pemphigus vulgaris.
    Olszewska M; Kolacinska-Strasz Z; Sulej J; Labecka H; Cwikla J; Natorska U; Blaszczyk M
    Am J Clin Dermatol; 2007; 8(2):85-92. PubMed ID: 17428113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Refractory pemphigus vulgaris treated with rituximab and mycophenolate mofetil.
    Biot Sdel R; Franco JP; Lima RB; Pereira HN; Marques LP; Martins CJ
    An Bras Dermatol; 2014; 89(6):980-4. PubMed ID: 25387507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mycophenolate mofetil as adjuvant in pemphigus vulgaris.
    Sarma N; Ghosh S
    Indian J Dermatol Venereol Leprol; 2007; 73(5):348-50. PubMed ID: 17921620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pemphigus: a review].
    Joly P; Sin C
    Ann Dermatol Venereol; 2011 Mar; 138(3):182-200. PubMed ID: 21397148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant therapy of pemphigus.
    Bystryn JC
    Arch Dermatol; 1984 Jul; 120(7):941-51. PubMed ID: 6375579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of plasmapheresis therapy on circulating levels of pemphigus antibodies.
    Tan-Lim R; Bystryn JC
    J Am Acad Dermatol; 1990 Jan; 22(1):35-40. PubMed ID: 2298963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comprehensive analysis of treatment outcomes in patients with pemphigus vulgaris treated with rituximab.
    Ahmed AR; Shetty S
    Autoimmun Rev; 2015 Apr; 14(4):323-31. PubMed ID: 25499920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of Guidelines for Management of Pemphigus: a Review of Systemic Corticosteroids, Rituximab, and Other Immunosuppressive Therapies.
    Zhao W; Wang J; Zhu H; Pan M
    Clin Rev Allergy Immunol; 2021 Dec; 61(3):351-362. PubMed ID: 34350539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Herpes esophagitis in the setting of immunosuppression from pemphigus vulgaris therapy.
    Kahn NH; Friedmann DP; Phillips CM
    Cutis; 2015 Jan; 95(1):44-6. PubMed ID: 25671444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recalcitrant pemphigus vulgaris responding to systemic tacrolimus.
    Büsing V; Kern JS; Bruckner-Tuderman L; Hofmann SC
    Dermatology; 2010; 221(2):122-6. PubMed ID: 20587990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.